An exploratpry study of the correlation of effects of memantine for cognitive function/BPSD and functional alterations on image of FDG-PET/SPECT in moderate Alzheimer's disease patient
Not Applicable
- Conditions
- Moderate Alzheimer's Disease
- Registration Number
- JPRN-UMIN000016420
- Lead Sponsor
- Sunagawa City Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Dementia other than AD 2) Significant neurologic desease 3) Other muscloskeletal complication which may affects implementing cognitive assessments 4) Significant psychiatric disorder 5) History of alcoholism or drug addiction 6) History of severe drug allegy 7) Other clinically important or uncontrolled diseases at the time of screening 8) Use of investigational medications within 60 days prior to screening etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FDG-PET, SPECT, MMSE and NPI after 12 weeks
- Secondary Outcome Measures
Name Time Method - FDG-PET, SPECT, MMSE and NPI after 52 weeks - Safety information